RT Journal Article
T1 Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke
A1 Pelaz García, Beatriz
A1 Correa Paz, Clara
A1 Pérez Mato, María
A1 Kurisky, Brian Patrick
A1 Zhang, Issan
A1 Marie, Pauline P.
A1 Hervella, Pablo
A1 Rubio, Marina
A1 Maysinger, Dusica
A1 Vivien, Denis
A1 Pino González de la Higuera, Pablo Alfonso del
A1 Polo Tobajas, Ester
A1 Migliavacca, Martina
A1 Campos Pérez, Francisco
K1 Thrombolytic therapy
K1 ischemic stroke
K1 Cellsomes
K1 lyophilized platelet-derived nanocarriers
K1 ictus cerebral
AB Intravenous administration of fibrinolytic drugs, such as recombinant tissue plasminogen activator (rtPA) is the standard treatment of acute thrombotic diseases. However, current fibrinolytics exhibit limited clinical efficacy because of their short plasma half-lives and risk of hemorrhagic transformations. Platelet membrane-based nanocarriers have received increasing attention for ischemic stroke therapies, as they have natural thrombus-targeting activity, can prolong half-life of the fibrinolytic therapy, and reduce side effects. In this study we have gone further in developing platelet-derived nanocarriers (defined as cellsomes) to encapsulate and protect rtPA from degradation. Following lyophilization and characterization, their formulation properties, biocompatibility, therapeutic effect, and risk of hemorrhages were later investigated in a thromboembolic model of stroke in mice.
PB Springer
SN 1477-3155
YR 2024
FD 2024
LK http://hdl.handle.net/10347/33665
UL http://hdl.handle.net/10347/33665
LA eng
NO Migliavacca, M., Correa-Paz, C., Pérez-Mato, M., Bielawski, P.B., Zhang, I., Marie, P., Hervella, P., Rubio, M., Maysinger, D., Vivien, D., Pino, P. del, Pelaz, B., Polo, E., Campos, F.  (2024). Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke . "Journal of Nanobiotechnology", vol. 22, 10
DS Minerva
RD 30 abr 2026